A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies.

Trial Profile

A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2011

At a glance

  • Drugs Paclitaxel; Tanespimycin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jul 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 16 May 2011 Planned initiation date changed from 1 Feb 2009 to 1 Apr 2012 as reported by ClinicalTrials.gov.
    • 16 May 2011 Planned End Date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top